- Case-Based Modules
- Initial Evaluation
- Dermatologic Manifestations
- Oral Manifestations
- OIs: Prophylaxis
- OIs: Treatment
- Antiretroviral Rx
- Antiretroviral Rx: Resistance
- Antiretroviral Rx: Adverse Effects
- Drug-Drug Interactions
- Postexposure Prophylaxis
- Perinatal Transmission
- Special Populations
- Prevention for Positives
- Challenging Unknowns
- Resource-Limited Settings
- Interactive Tutorials
- Routine HIV Screening
- Oraquick Advance Rapid HIV Test
- HIV Integration
- This program is funded through Health Resources and Services Administration, US Department of Health and Human Services.
Special Populations
Question | Discussion | References | CME Credit
Case 2: Heroin Use and HIV
You answered:
 |
In the United States, buprenorphine may now be provided legally through outpatient medical clinics, but physicians who intend to prescribe buprenorphine are required to undergo special training and receive a waiver from the SAMHSA Center for Substance Abuse Treatment. |
|---|
This answer is correct. Buprenorphine was the first schedule III medication to receive approval under the Drug Addiction Treatment Act of 2000 (DATA 2000) for use by physicians in office-based treatment programs. Physicians interested in prescribing buprenorphine need to undergo special training and receive a waiver from the Center for Substance Abuse and Treatment.
Copyright © 2004-2013 University of Washington